Healthcare stocks were leaning lower premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.4% and the iShares Biotechnology ETF (IBB) down 0.1%.
Definium Therapeutics (DFTX) shares were up more than 16% after the company said its phase 3 Voyage study of DT120 lysergide orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.
Arbutus Biopharma (ABUS) stock was down more than 3% after the company reported that it swung to a Q2 loss as revenue fell during the period.
Natera's (NTRA) Latitude tissue-free assay for molecular residual disease detection will be used by Kupando Therapeutics in a phase 1 clinical trial of its lead immunotherapy candidate, KUP-101, Natera said. Shares of Natera were up more than 1% pre-bell.